sanofi aventis sa obesity drug acomplia to get june fda review sanofi aventis sa said its obesity drug acomplia will be evaluated by a food and drug administration panel in june acomplia already introduced in europe is the most important drug in the french pharmaceutical makers portfolio analysts estimate annual sales of &# billion to &# billion if it wins u s approval an fda advisory committee will discuss its efficacy and safety as a treatment for obesity in a meeting set for june while acomplia received conditional approval from the fda in february the final green light has been delayed 
